AU2014278037A1 - Compositions and methods for the treatment of Burkholderia infections - Google Patents

Compositions and methods for the treatment of Burkholderia infections Download PDF

Info

Publication number
AU2014278037A1
AU2014278037A1 AU2014278037A AU2014278037A AU2014278037A1 AU 2014278037 A1 AU2014278037 A1 AU 2014278037A1 AU 2014278037 A AU2014278037 A AU 2014278037A AU 2014278037 A AU2014278037 A AU 2014278037A AU 2014278037 A1 AU2014278037 A1 AU 2014278037A1
Authority
AU
Australia
Prior art keywords
antibody
polypeptide
seq
ihf
biofilm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014278037A
Other languages
English (en)
Inventor
Amal AMER
Lauren O. Bakaletz
Steven D. Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Nationwide Childrens Hospital Inc
Ohio State Innovation Foundation
Original Assignee
University of Southern California USC
Nationwide Childrens Hospital Inc
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC, Nationwide Childrens Hospital Inc, Ohio State Innovation Foundation filed Critical University of Southern California USC
Publication of AU2014278037A1 publication Critical patent/AU2014278037A1/en
Priority to AU2018202762A priority Critical patent/AU2018202762C1/en
Priority to AU2020203092A priority patent/AU2020203092A1/en
Priority to AU2023202534A priority patent/AU2023202534A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2014278037A 2013-06-13 2014-06-12 Compositions and methods for the treatment of Burkholderia infections Abandoned AU2014278037A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2018202762A AU2018202762C1 (en) 2013-06-13 2018-04-20 Compositions and methods for the treatment of burkholderia infections
AU2020203092A AU2020203092A1 (en) 2013-06-13 2020-05-11 Compositions and methods for the treatment of burkholderia infections
AU2023202534A AU2023202534A1 (en) 2013-06-13 2023-04-27 Compositions and methods for the treatment of burkholderia infections

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834846P 2013-06-13 2013-06-13
US61/834,846 2013-06-13
PCT/US2014/042201 WO2014201305A1 (en) 2013-06-13 2014-06-12 Compositions and methods for the treatment of burkholderia infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202762A Division AU2018202762C1 (en) 2013-06-13 2018-04-20 Compositions and methods for the treatment of burkholderia infections

Publications (1)

Publication Number Publication Date
AU2014278037A1 true AU2014278037A1 (en) 2016-01-07

Family

ID=51177157

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014278037A Abandoned AU2014278037A1 (en) 2013-06-13 2014-06-12 Compositions and methods for the treatment of Burkholderia infections
AU2018202762A Active AU2018202762C1 (en) 2013-06-13 2018-04-20 Compositions and methods for the treatment of burkholderia infections
AU2020203092A Abandoned AU2020203092A1 (en) 2013-06-13 2020-05-11 Compositions and methods for the treatment of burkholderia infections
AU2023202534A Pending AU2023202534A1 (en) 2013-06-13 2023-04-27 Compositions and methods for the treatment of burkholderia infections

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2018202762A Active AU2018202762C1 (en) 2013-06-13 2018-04-20 Compositions and methods for the treatment of burkholderia infections
AU2020203092A Abandoned AU2020203092A1 (en) 2013-06-13 2020-05-11 Compositions and methods for the treatment of burkholderia infections
AU2023202534A Pending AU2023202534A1 (en) 2013-06-13 2023-04-27 Compositions and methods for the treatment of burkholderia infections

Country Status (7)

Country Link
US (1) US20160175440A1 (enExample)
EP (1) EP3008088B1 (enExample)
JP (8) JP2016521752A (enExample)
AU (4) AU2014278037A1 (enExample)
CA (1) CA2915210A1 (enExample)
ES (1) ES2746971T3 (enExample)
WO (1) WO2014201305A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012010793A (es) 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
WO2012034090A1 (en) 2010-09-09 2012-03-15 University Of Southern California Compositions and methods for the removal of biofilms
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
EP3536168A3 (en) 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
WO2016154491A1 (en) * 2015-03-25 2016-09-29 Trellis Bioscience, Llc Binding moieties for biofilm remediation
HK1255383A1 (zh) * 2015-07-31 2019-08-16 The Research Institute At Nationwide Children's Hospital 去除生物膜的肽及抗體
EP3365027B1 (en) * 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
AU2018206552C1 (en) * 2017-01-04 2025-04-10 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
EP3565834B1 (en) * 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
MX2021003838A (es) 2018-10-05 2021-05-27 Res Inst Nationwide Childrens Hospital Derivados de proteina hmgb1 para la eliminacion de biopeliculas.
US12161701B2 (en) * 2018-10-05 2024-12-10 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
CA3142272A1 (en) 2019-06-03 2020-12-10 Research Institute At Nationwide Children's Hospital Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
WO2023228443A1 (ja) 2022-05-24 2023-11-30 株式会社オクト バイオフィルムを破壊するための溶液及びその製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102497883B (zh) * 2009-06-03 2014-06-11 阿尔吉法玛公司 用于克服细菌多重抗药性的藻酸盐低聚物
EP2473170B1 (en) * 2009-09-04 2019-06-19 Horizon Orphan LLC Use of aerosolized levofloxacin for treating cystic fibrosis
MX2012010793A (es) * 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
WO2012034090A1 (en) * 2010-09-09 2012-03-15 University Of Southern California Compositions and methods for the removal of biofilms

Also Published As

Publication number Publication date
EP3008088B1 (en) 2019-08-21
AU2020203092A1 (en) 2020-05-28
US20160175440A1 (en) 2016-06-23
JP2019010122A (ja) 2019-01-24
JP2022116236A (ja) 2022-08-09
JP2016521752A (ja) 2016-07-25
JP2023072074A (ja) 2023-05-23
JP6832901B2 (ja) 2021-02-24
WO2014201305A1 (en) 2014-12-18
JP2020037595A (ja) 2020-03-12
ES2746971T3 (es) 2020-03-09
JP2024060001A (ja) 2024-05-01
JP2017143841A (ja) 2017-08-24
AU2018202762B2 (en) 2020-07-02
HK1222398A1 (en) 2017-06-30
JP2025122007A (ja) 2025-08-20
AU2018202762A1 (en) 2018-05-10
AU2018202762C1 (en) 2020-10-01
AU2023202534A1 (en) 2023-05-18
EP3008088A1 (en) 2016-04-20
CA2915210A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
AU2018202762B2 (en) Compositions and methods for the treatment of burkholderia infections
US12239763B2 (en) Peptides and antibodies for the removal of biofilms
US12419944B2 (en) DNABII vaccines and antibodies with enhanced activity
EP3997120A2 (en) Antibody compositions for disrupting biofilms
EP3861021B1 (en) Compositions and methods for enzymatic disruption of bacterial biofilms
US20230272054A1 (en) Combination therapies for the treatment and prevention of biofilms
HK1222398B (en) Compositions and methods for the treatment of burkholderia infections
HK40059379B (en) Compositions and methods for enzymatic disruption of bacterial biofilms
HK40059379A (en) Compositions and methods for enzymatic disruption of bacterial biofilms

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period